Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Modified Ketogenic Diet in Patients With McArdle Disease Part B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04044508
Recruitment Status : Recruiting
First Posted : August 5, 2019
Last Update Posted : August 5, 2019
Sponsor:
Collaborator:
University College, London
Information provided by (Responsible Party):
Nicoline Løkken, Rigshospitalet, Denmark

Brief Summary:

McArdle disease, glycogen storage disease type V, is a rare metabolic disease. Affected individuals are unable to utilize sugar stored as glycogen in muscle. Investigators hypothesize that a modified ketogenic diet could be a potential treatment option, by providing ketones as alternative fuel substrates for working muscle.

This blinded, placebo-controlled, cross-over study will investigate the potential effects of an optimal modified ketogenic diet found in part A (75% fat, 15%protein, 10%carbohydrates) in patients with McArdle disease compared with a healthy balanced placebo diet (>100grams of carbohydrates per day).


Condition or disease Intervention/treatment Phase
McArdle Disease Dietary Supplement: Ketocal 4:1 liquid Nutricia (intervention) Dietary Supplement: Fortini multifibre Nutrica (placebo) Not Applicable

Detailed Description:

A blinded randomized, placebo-controlled, cross-over study to investigate the effects of a modified ketogenic diet in patients with McArdle disease.

McArdle disease, glycogen storage disease type V, is a rare metabolic disease caused by mutations in the PYGM gene resulting in absence of the enzyme muscle phosphorylase. Affected individuals are unable to utilize sugar stored as glycogen in muscle, leading to exercise intolerance, exercise-induced muscle pain, contractures and rhabdomyolysis. Currently, there are no satisfactory treatment options for McArdle disease. Ketones are feasible fuel alternatives to muscle glycogen when muscle glycogenolysis is blocked as in McArdle disease. A key element of alleviating symptoms in McArdle disease is to provide alternative fuels for energy metabolism. Ketosis can potentially provide alternative fuel substrates by provision of endogenous ketone bodies (KBs) which are desirable fuels for skeletal muscle and brain. Ketosis can be reached by fasting and can be induced by adhering to a modified ketogenic diet, which entails a high-fat, low-carbohydrate diet, which simulates the metabolic effects of fasting.

The study design is a placebo-controlled, blind, cross over design. The study will be carried out at two sites: CNMC (Copenhagen), NHNN (London). Subjects will be randomized 1:1 to receive either a modified ketogenic diet (75% fat, 15%protein, 10% carbohydrates) or a placebo diet (>100grams of carbohydrates per day) first. Subjects will follow the diet for 4 weeks, followed by 2-4 weeks wash-out, followed by 4 weeks on the opposite diet. During the 10-12 weeks trial period, subjects will visit the trial site in London on five occasions. Effects of the diet will be evaluated by improvement in exercise capacity during submaximal exercise test on a cycle ergometer. Subjective improvements will be evaluated by questionnaires and a dietary diary.

If the diet improves exercise capacity, it will provide a safe and cheap treatment option that may lead to reduced risk of muscle injury and enhance quality of life in patients with McArdle disease.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Randomized, blind, placebo-controlled, cross over study
Masking: Double (Participant, Investigator)
Masking Description: Disguise products (Oral supplements: Nutricia 'ketocal' (intervention) or Nutricia 'fortini' (placebo)
Primary Purpose: Treatment
Official Title: Odified Ketogenic Diet in Patients With McArdle Disease Part B - a Placebo-controlled, Cross-over Study
Estimated Study Start Date : August 3, 2019
Estimated Primary Completion Date : March 1, 2021
Estimated Study Completion Date : March 1, 2022


Arm Intervention/treatment
Active Comparator: Interventional diet
A modified ketogenic diet (with the composition found in the pilot study, 75%fat, 15% protein, 10% carbohydrates)
Dietary Supplement: Ketocal 4:1 liquid Nutricia (intervention)
Modified ketogenic diet

Placebo Comparator: Placebo diet
A placebo diet (over 100 g of carbohydrates per day)
Dietary Supplement: Fortini multifibre Nutrica (placebo)
Placebo diet




Primary Outcome Measures :
  1. Change in mean heart rate [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Change in mean heart rate (bpm) during constant load cycling exercise (30 minute submaximal cycle test). Heart rate will be measured every minute during the cycle test at all visits.


Secondary Outcome Measures :
  1. Compliance [ Time Frame: up 12 weeks ]
    Daily dietary diary

  2. Change in Indirect calorimetry [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Oxidation rates measured via indirect calorimetry during constant load cycling Measured at visit 1-4.

  3. Change in self-rated daily function scores [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Modified SF-36 questionnaire

  4. Change in self-rated fatigue [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Fatigue Severity Scale score

  5. Change in blood ketones [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Ketone bodies in the blood (hydroxybutyrate+acetoacetate umol/L).

  6. Change in perceived exertion [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Borg scale (scale from 6-20). During the constant load cyclinging test, subjects will be asked every minute during.

  7. Change in ammonia [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Blood Ammonia (umol/L). Will be measured 5 times during the cycle test at visit 1-4.

  8. Change in insulin [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Blood Insulin (pmol/l). Will be measured 6 times during the cycle test at visit 1-4.

  9. Change in Adrenalin [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Blood Adrenalin (pg/mL) Will be measured 6 times during the cycle test at visit 1-4.

  10. Change in glucagon [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Blood Glucagon (pmol/L). Will be measured 4 times during the cycle test at visit 1-4.

  11. Change in maximal oxygen capacity [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    (VO2max, mL oxgen per minute) after the 30 minutes submaximal exercise test, the workload will be increased in a step vise manner to maximum.

  12. Change in maximal work load [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Work load (watts) after the 30 minutes submaximal exercise test, the workload will be increased in a step vise manner to maximum.

  13. Change in free fatty acids [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Blood Free fatty acids (umol/L). Will be measured 6 times during the cycle test at visit 1-4.

  14. Change in lactate [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Blood Lactate (mM). Will be measured 6 times during the cycle test at visit 1-4.

  15. Change in glucose [ Time Frame: At Visit 1 (baseline), Visit 2 (4 weeks), Visit 3 (8 weeks), and Visit 4 (12 weeks) ]
    Blood glucose (mM). Will be measured 6 times during the cycle test at visit 1-4.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Genetically confirmed GSDV
  • Patient is willing and able to provide written informed consent prior to participation.
  • Patient is ambulatory.
  • Women in fertile age must be willing to practice the following medically acceptable methods of birth control

Exclusion Criteria:

  • Patient has any prior or current medical conditions that, in the judgment of the Investigator, would prevent the patient from safely participating in and/or completing all study requirements.
  • Pregnancy or breastfeeding
  • Patient does not have the cognitive capacity to understand/comprehend and complete all study assessments
  • Patients with porphyria or disorders of fat metabolism (primary carnitine deficiency, carnitine palmitoyltransferase I or II, β-oxidation defects etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04044508


Contacts
Layout table for location contacts
Contact: Nicoline Løkken +45 35458748 nicoline.loekken@regionh.dk

Locations
Layout table for location information
Denmark
Copenhagen Neuromuscular Center, Rigshospitalet Recruiting
Copenhagen, Denmark
Contact: Nicoline Løkken    +45 3545 8748    nicoline.loekken@regionh.dk   
United Kingdom
National Hospital for Neurology and neurosurgery Not yet recruiting
London, United Kingdom
Contact: Kit Kaalund Hansen    0203 448 3605 ext 83605    kit.kaalundhansen@nhs.net   
Sponsors and Collaborators
Rigshospitalet, Denmark
University College, London

Layout table for additonal information
Responsible Party: Nicoline Løkken, MD, Research fellow, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT04044508     History of Changes
Other Study ID Numbers: H-18013022-B
First Posted: August 5, 2019    Key Record Dates
Last Update Posted: August 5, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Glycogen Storage Disease Type V
Glycogen Storage Disease
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases